One Of Mark Lampert’s Small-Cap Biotech Picks Has Returned 84% This Year And It’s Not Done Yet

Mark Lampert’s Biotechnology Value Fund recently filed its 13F with the U.S. Securities and Exchange Commission for the reporting period of March 31.

Keep Reading →